spinal muscular atrophy

Showing 5 posts of 20 posts found.

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019
Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …

roche_side_building

Roche resigns itself to failure on SMA drug

June 1, 2018
Medical Communications Roche, biotech, drugs, pharma, pharmaceutical, spinal muscular atrophy

Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …

EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza

April 25, 2017
Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy

Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …

biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

Latest content